Xencor, Inc. XNCR 深 沪
已收盘 04-02 16:00:00 美东时间
12.81
+0.280
+2.23%
华盛通- 最 高12.825
- 今 开12.21
- 成交量 60.85万股
- 最 低 12.20
- 昨 收 12.53
- 总市值 9.39亿
- 52周最高 18.69
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 6.92
- 委 比 -88.53%
- 总股本 7333.86万
- 历史最高 58.345
- 量 比 0.65
- 振 幅 4.99%
- 历史最低 5.75
- 每 手 1
- 风险率 2.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.
03-25 00:02
JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13
JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $18 to $13.
03-24 20:08
Xencor, Genentech to End Protein Therapeutics Collaboration
Xencor ( ($XNCR) ) just unveiled an update. Xencor, Inc., a biopharmaceutical d...
03-10 04:46
Xencor shares are trading lower after Alexion Pharmaceuticals informed the company it does not owe additional royalties for Ultomiris sales in the U.S.
Xencor shares are trading lower after Alexion Pharmaceuticals informed the comp...
03-06 01:02
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.
03-05 19:00
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Xencor shares are trading higher after the company reported better-than-expected Q4 EPS results.
Xencor shares are trading higher after the company reported better-than-expecte...
02-26 23:27
Xencor Q4 EPS $(0.09) Beats $(0.54) Estimate, Sales $28.200M Miss $31.686M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.54) by 83.43 percent. This is a 85.48 percent increase over losses of $(0.62) per share from the same
02-26 05:42
Xencor to Present at TD Cowen, Leerink Partners, and Barclays Healthcare Conferences
Xencor to Present at TD Cowen, Leerink Partners, and Barclays Healthcare Conferences Xencor Inc. said its management will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, and the Barclays 28th A
02-24 05:01
